Salmon

Private equity investors interested in acquiring leading fish health company

'The deal is expected to close before the summer,' a financial advisor told IntraFish.

In 2021, STIM built a facility to develop an organism that could be key to reducing antibiotic-resistant bacteria in farmed fish and other animals -- including humans.
In 2021, STIM built a facility to develop an organism that could be key to reducing antibiotic-resistant bacteria in farmed fish and other animals -- including humans.Photo: Anders H. Furuset
Published 17 January 2024, 05:00Updated 17 January 2024, 05:00
NorwayABG Sundal CollierSTIMFish healthMergers & Acquisitions